NGL Fine Chem Ltd
Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]
- Market Cap ₹ 1,231 Cr.
- Current Price ₹ 1,992
- High / Low ₹ 2,440 / 1,161
- Stock P/E 36.9
- Book Value ₹ 393
- Dividend Yield 0.09 %
- ROCE 11.5 %
- ROE 9.31 %
- Face Value ₹ 5.00
Pros
Cons
- Debtor days have increased from 71.3 to 86.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
36 | 56 | 79 | 88 | 96 | 100 | 114 | 153 | 152 | 258 | 319 | 275 | 293 | |
32 | 48 | 68 | 73 | 74 | 74 | 92 | 121 | 129 | 181 | 253 | 246 | 252 | |
Operating Profit | 4 | 8 | 11 | 15 | 22 | 25 | 22 | 32 | 23 | 77 | 66 | 29 | 40 |
OPM % | 11% | 14% | 14% | 17% | 23% | 26% | 19% | 21% | 15% | 30% | 21% | 10% | 14% |
0 | 0 | -1 | 2 | 0 | 1 | 3 | 4 | 1 | 9 | 13 | 8 | 12 | |
Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 1 |
Depreciation | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 6 | 7 | 7 | 8 | 8 | 8 |
Profit before tax | 2 | 4 | 7 | 13 | 18 | 23 | 18 | 28 | 14 | 76 | 69 | 27 | 43 |
Tax % | 32% | 35% | 32% | 35% | 36% | 35% | 29% | 27% | 26% | 27% | 24% | 24% | |
1 | 3 | 5 | 8 | 11 | 15 | 13 | 20 | 11 | 55 | 52 | 20 | 33 | |
EPS in Rs | 1.70 | 4.71 | 7.33 | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 17.16 | 89.79 | 84.57 | 32.57 | 54.07 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 10% | 2% | 2% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 19% |
3 Years: | 22% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 10% |
3 Years: | 19% |
TTM: | 38% |
Stock Price CAGR | |
---|---|
10 Years: | 57% |
5 Years: | 34% |
3 Years: | 15% |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 23% |
3 Years: | 24% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 14 | 17 | 21 | 30 | 41 | 56 | 69 | 89 | 98 | 152 | 203 | 222 | 240 |
10 | 13 | 17 | 13 | 14 | 23 | 27 | 27 | 28 | 16 | 30 | 32 | 27 | |
10 | 14 | 15 | 21 | 19 | 20 | 31 | 23 | 26 | 34 | 41 | 30 | 52 | |
Total Liabilities | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 288 | 322 |
10 | 18 | 19 | 17 | 24 | 25 | 56 | 61 | 61 | 58 | 59 | 59 | 58 | |
CWIP | 5 | 0 | 0 | 1 | 2 | 16 | 3 | 0 | 0 | 1 | 6 | 26 | 33 |
Investments | 2 | 0 | 0 | 2 | 3 | 6 | 6 | 9 | 14 | 33 | 32 | 43 | 51 |
21 | 30 | 37 | 46 | 49 | 55 | 63 | 73 | 80 | 115 | 180 | 159 | 180 | |
Total Assets | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 288 | 322 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | -0 | -0 | 8 | 8 | 10 | 22 | 9 | 20 | 27 | 13 | 32 | |
-4 | -3 | -4 | -3 | -10 | -10 | -21 | -10 | -19 | -24 | -13 | -24 | |
3 | 4 | 3 | -4 | 2 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | |
Net Cash Flow | -0 | 1 | -1 | 1 | 0 | -0 | 1 | -1 | -0 | 2 | -1 | 7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 115 | 100 | 110 | 107 | 123 | 110 | 89 | 79 | 63 | 53 | 74 | 86 |
Inventory Days | 113 | 126 | 77 | 106 | 90 | 114 | 134 | 106 | 154 | 132 | 133 | 69 |
Days Payable | 156 | 148 | 105 | 150 | 122 | 139 | 187 | 92 | 114 | 94 | 84 | 59 |
Cash Conversion Cycle | 72 | 78 | 82 | 63 | 91 | 85 | 35 | 93 | 103 | 91 | 124 | 97 |
Working Capital Days | 81 | 88 | 88 | 77 | 96 | 85 | 54 | 107 | 98 | 78 | 116 | 104 |
ROCE % | 11% | 19% | 24% | 29% | 37% | 34% | 22% | 28% | 15% | 52% | 35% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 Nov - The Company participated in the Investors Conference Call on Monday, 20th November, 2023, enclosed herewith please find transcript of earnings conference call on unaudited Financial …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 Nov - The Company participated in the Investors Conference Call on Monday, 20th November, 2023, enclosed herewith please find transcript of earnings conference call on unaudited Financial …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 Nov - The Company participated in the Investors Conference Call on Monday, 20th November, 2023, enclosed herewith please find transcript of earnings conference call on unaudited Financial …
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 23 Nov
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 20 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT REC
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
Dec 2019TranscriptPPT
Product Portfolio Q2FY24
Presently, Veterinary APIs are the main product of the company which account for 83% of its revenues, followed by Veterinary Formulations (6%), Human APIs (6%), and others (5%).[1] The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms.[2]